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Summarv To studv the effect of localised secretion of chemokines on tumour growth. the genes for human
(hu interleukin 8 (IL-8). hu-MCP-1 (NICAF). hu-MIP-12 (LD78). murine (mu)-MCP-1 (JE). mu-MIP-lx or
mu-MIP-2 A-ere introduced. v-ia mammalian expression vectors. into Chinese hamster ovarv (CHO) cells. and
the abilitv of transfected cells to form tumours in vivo uas evaluated. The production of hu-IL-8. hu-MIP-lx
or mu-MIP-lx bv transfected clones did not influence the growth rate in iitro. but drastically suppressed
tumour growth A-hen injected subcutaneouslv (s.c.) into nude mice. However. clones transfected with hu-MCP-
1. mu-NMCP-I or mu-MIP-2 did not shou- anv significant difference in growth rate in vivo compared u-ith
clones transfected u-ith sector alone. Histological examination of the site of injection of CHO clones
transfected w-ith hu-IL-8. hu-MIP-l1 or mu-MIP-lE showed predominantly neutrophilic infiltration. These
results indicate that chemokines have potent anti-tumour activitv A-hen released. even at lou- doses. at the
tumour site. A-hich mav be mediated by recruitment and targeting of neutrophilic granulocvtes to chemokine-
releasing cells. Our studies highlight the potential usefulness of localised chemokine secretion in inducing
potent host anti-tumour defensive responses.
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Application of 'tumour cell-targeted cytokine gene therapy'
has proven useful in predicting or assessing the potential
anti-tumour activitv of a cvtokine in experimental animal
svstems. This approach has been used to investigate the
anti-tumour effects of interleukin 2 (IL-2) (Gansbacher et al..
1990). IL-4 (Tepper et al.. 1989). IL-6 (Mullen et al.. 1992).
IL-7 (Hock et al.. 1991). interferon a (IFN-<) (Ferrantini et
al.. 1993). IFN-y (W'atanabe et al.. 1989). tumour necrosis
factor alpha (TN-F-) (Blankenstein et al.. 1991). granulocyte
colony-stimulating factor (G-CSF) (Colombo et al.. 1991)
and granulocyte-macrophage (GM)-CSF (Columbec et al..
1993).
Although the chemokines IP-10 (interferon-inducible pro-
tein 10) (Luster et al.. 1985) and MCP-1 (MCAF. JE)
(monoc-te chemotactic protein 1) (Matsushima et al.. 1989)
have recently been reported to has-e potent anti-tumour
activitv in vivo (Bottazi et al.. 1992: Rollins and Sundav.
1992: Luster and Leder. 1993). the other chemokine famils
members has-e not. thus far. been reported to have anti-
tumour effects.
The chemokines are a superfamily of small proteins (M.U
8000- 14 000) secreted primarilv by leucocvtes and related by
a conserved four-cvsteine motif. The superfamily s two bran-
ches are classified as the C-X-C and C-C groups. as defined
by spacing of the first txs-o cysteins in the conserved motif
(Oppenheim et al.. 1991). Generallv. C-X-C chemokines.
such as IL-8 (the neutrophil attractant and activating factor)
(Oppenheim et al.. 1991). GRO MGSA (melanoma growth-
stimulatorx factor) (Anisowicz et al.. 1987). IP-10 (Luster et
al.. 1985). and MIP-2 (macrophage inflammatory protein-2)
(Wolpe and Cerami. 1989). are potent chemoattractants and
activators for neutrophils (Oppenheim et al.. 1991). whereas
the C-C chemokines. including such molecules as MCP-1
(Matsushima et al.. 1989). MIP-lh (LD78) (Wolpe and
Cerami. 1989). and RANTES (rezulated on activation. nor-
mal T expressed and secreted) (Schall et al.. 1990) exhibit
Correspondence: K Hirose
Received 2 December 1994. revised 19 Apnrl 1995: accepted 28 Apnrl
1995
chemoattractant potential for monocytes and T lymphocytes
(Oppenheim et al.. 1991). The accumulation and activation of
leucocvtes at sites of inflammation is induced by locally
produced and secreted chemokines.
Since the chemokines has-e been reported to attract and
stimulate immune cells. we has-e. therefore. evaluated the
tumorngenicity and host anti-tumour response in mice given
injections of CHO cells genetically modified to secrete
chemokines. We has-e used nude mice to circumvent allo-




Approximately 1.7 kb of hu-IL-8 cDNA and 0.33 kb of hu-
MCP-1 cDNA A-ere isolated from a cDNA librarx of
lipopolysaccharide (LPS)-stimulated human peripheral blood
mononuclear cells (PBMCs) and a phorbol l2-mvristate 13-
acetate (PMA)-pretreated monocvtic cell hne (THP-1) respec-
tivelv (Matsushima et al.. 1988: Furutani et al.. 1989). and
ligated into the BamHI HindIII-digested mammalian expres-
sion vector pHpApr-3p-neo (Gunning et al.. 1987). The other
chemokine cDNAs were isolated by poly-merase chain reac-
tion (PCR) using reverse transcribed total RNA of PMA plus
phytohaemagglutinin (PHA)-activated human PBMCs for
hu-MIP-Ix (LD78) and LPS-stimulated mouse splenic cells
for mu-MIP-lx. mu-MIP-2 and mu-MCP-1 according to
published protocols (Lipson and Baserga. 1989). The follow-
ing primers were used: for hu-MIP-lcx (Obuku et al.. 1986): 5'-
GTGAAGCTTCAGACAGTGGTCAGTCCTTTC-3' and 5'-
CACGGATCCCCCTCAGGCACTCAGCTCTA-3': for mu-
MCP-1 (Kawahara and Deuel. 1989): 5'-GTGAAGCTTAG-
CTCTCTCTTCCTCCACCACCA-3' and 5'-CACGGATC-
CTTTACGGGTCAACTTCACATTCAAA-3': for mu-MIP-
lx (Wolpe et al.. 1988): 5'-GTGAAGCTTCTCACCCTC-
TGTCACCTGCTCAA-3' and 5'-CACGGATCCGGCTCA-
AGCCCCTGCTCTACAC-3': for mu-MIP-2 (Wolpe et al..
1989): 5'-GTGAAGCTTAGCCACACTTCAGCCTAGCG-CC-3' and 5'-CACGGATCCTTTCCAGGTCAGTTAGCC-
TTGCC-3'. DNA fragments were cloned into the BamHl/
HindII site of vector pUCl19 followed by confirmation of
nucleotide sequences using automatic DNA sequencer DSQ-l
(Shimazu, Kyoto, Japan) and then ligated into BamHI
HindIII-digested pHiApr-3p-neo.
DNA transfection
CHO cells lines (ATCC. CCL61) were maintained in RPMI-
1640 medium supplemented with 100 units ml-' of penicillin
G, l00fgmP-' of streptomycin and 10% fetal calf serum
(FCS; Hyclone Laboratory, Logan, VT. USA). Subconfluent
cultures in 100 mm petri dishes were transfected with
chemokine expression plasmids or vector alone in lipofectin
(Gibco, Bethesda. MD, USA). After 48 h G418 (Geneticin;
Gibco) at 600ligmlm' (active form) was added to the cells
for selection. G418-resistant clones were randomly selected,
isolated and expanded individually.
Northern blot analvsis
Total RNA was prepared by guanidium isothiocyanate lysis
followed by caesium chloride gradient ultracentrifugation.
RNA (10 tg) from chemokine transfectants was denatured in
formaldehyde formamide, separated by electrophoresis in the
presence of formaldehyde on a 1.0% agarose gel and trans-
ferred to a nylon membrane filter (Schleich & Schull, Keens,
NH, USA). Filters were prehybridised for 16h at 42°C in
Hybrisol 1 (Oncor. Gaithersburg, MD, USA) and hybridised
with 32P-labelled chemokine cDNA (specific activity
>5 x I0O c.p.m. pg- ) at 42'C in the presence of 50% for-
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dodecyl sulphate (SDS) at room temperature. followed by
two washes in 0.2 x SSC. 01% SDS at 65'C for 30 min and
then exposed to Kodak X-OMAT. AR X-ray film (Eastman
Kodak, Rochester. NY. USA) with intensifier screens at
-70°C for 24 h.
Measurement ofchemokines by radio immunoassav (RIA) or
enzXYme-linked immunosorbent assa !(ELISA)
One million CHO transfectants in 1 ml of culture medium
were incubated in a 24-well culture plate at 37°C for 24 h.
The amount of hu-IL-8 and hu-MCP-1 in culture super-
natant was measured by RIA using a rabbit polyclonal anti-
hu-IL-8 or -hu-MCP-l antibody developed in our laboratory
(Endo et al., 1991). Both recombinant (r) IL-8 and rMCP-l
were labelled with '"I by the Bolton-Hunter method as
previously described (Matsushima et al.. 1986). Polyclonal
anti-IL-8 and -MCP-1 were obtained from New Zealand
white rabbits immunised s.c. with 100jig each of hu-IL-8 or
hu-MCP-1 with complete adjuvant (Sigma) four times at
weekly intervals and bled 1 week after final immunisation.
The production of hu-MIP-lx was measured using the hu-
MIP-l(x ELISA kit (R&D Systems, Minneapolis, MN, USA).
Preparation ofpolh morphonuclear leucocvites (PM-NVs> and
PBMC
Human polymorphonuclear leucocytes (PMNs) were used for
the chemotaxis assay of hu-IL-8. hu-MIP-lcx, mu-MIP-la,
and mu-MIP-2. PMNs were separated from peripheral blood
from healthy volunteers by Ficoll-Hypaque centnifugation.
followed by sedimentation on a gelatin solution [2.5% (w v)







Figure 1 Chemokine gene expression in CHO transfectants. Total RNA (10 jig) from (a) LPS-stimulated human PBMCs for
hu-IL-8. -MIP-z and -MCP-1. and LPS-stimulated mouse splenic cells for mu-MIP-lx. -MIP-2 and -MCP-1. (b) CHO cells
transfected with vector alone, or (c) CHO cells transfected with chemokine expression plasmids were electrophoresed. transferred to
nylon membrane filter, and hybridised with 32P-labelled chemokine cDNA as described in Materials and methods.3ummkine FM Cl_and tomairge
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rich fractions were collected and contaminating erythrocytes
were lysed with lysing solution (Ortho, Raritan, NJ, USA) by
incubation for 5 min at 25'C. The purity of PMNs was
>98% with more than 95% neutrophils. The chemotactic
activity of hu-, and mu- MCP-l was assayed using human
PBMC from healthy volunteers by Ficoll-Hypaque cent-
rifugation.
Chemotaxis assay
Neutrophil or monocyte chemotaxis assays were performed
using multimicro-well Boyden chamber (Neuroprobe, Cabin
John, MD, USA) as previously described (Falk et al., 1980).
A 25 1il aliquot of either supernatant (10-7 M N-formyl-
methionyl-leucyl-phenylalanine) (FMLP) (Sigma), hu-rIL-8
(1-100 ng ml-), hu-rMCP-1 (1-100 ng ml-l) or phosphate-
buffered saline (PBS) was placed in triplicate lower wells of
Boyden chambers. A 8tsm (for monocytes) or 3gm (for
neutrophils) pore size polycarbonate filter (Nucleopore,
Pleasanton, CA, USA) was placed in the assembly and 50pl
(1.5 x 106 cells ml-l) of PBMCs, or PMNs was placed in
each upper well. Chemotaxis chamber assemblies were
incubated at 37°C in humidified 95% air/5% carbon dioxide
for 1 h and filters were removed, fixed in 70% methanol and
stained with Diff-Quik 1 and 2 (Kokusai Shiyaku, Kobe,
Japan). Monocytes or PMNs that had migrated through onto
the lower surface of the filter were counted under the micro-
scope.
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Seven-week-old male BALB/c nulnu mice were purchased
from Nihon Crea (Atsugi, Japan). Transplantation assays for
each chemokine transfectant were performed successively in
combination with CHO/neo as a control. Tumour cell injec-
tions were carried out using freshly prepared suspensions at a
concentration of 1.5 x 107 cells ml'. The total number of
Table I Chemokine secretion after gene transfer into tumour
Productiona ActivitnJ
(ngml-' 10-6 cells (chemotactic index,
Tumour 24h-', mean ± s.d) mean ± s.d.)
CHO/hu-IL-8 4 1 2.5 ± 0.3*
CHO/hu-MIP-Im 7± 1 3.4 0.5**
CHO/hu-MCP-1 82 18 4.7 0.5**
CHO/mu-MIP-laz NT 5.1 ± 0.6**
CHO/mu-MIP-2 NT 5.8 ±1.1**
CHO/mu-MCP-1 NT 4.6 1.1**
CHO/neo 1.1 ±0.3
medium 1.0
'The amount of hu-IL-8 and hu-MCP-1 in culture supernatants
was measured by radioimmunoassay, and hu-MIP-la was assayed
using an ELISA system as described in Materials and methods. MThe
chemotactic activity was measured using a multimicro-well Boyden
chamber as described in Materials and methods. NT, not tested.
*P<0.01 vs medium (Student's t -test). **P<0.001 vs medium
(Student's t-test).

















Figure 2 Comparison of the growth of control and cbemokine-transfected CHO clones. Groups of six to nine mice were given
injections of 3 x 106 tumour cells. Tumour growth was monitored as described in Materials and methods. 0, chemok.ine
transfectant; 0, control transfectant (CHO/neo). *P<0.01 vs CHO/neo. **P<0.001 vs CHO/neo.Chemake pw trnsfer reducestu igenicity in Wm
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tumour cells injected per animal was 3 x 106. except for
mixed tumour transplantation assay (see below). All injec-
tions were performed s.c. in the right lower abdominal quad-
rant via 27 gauge needles. Tumour volumes were measured in
mm3 with a vernier caliper and recorded by the formula
(a x b2 2), where a is the larger and b is the smaller of the
two dimensions. All animal experiments were conducted in
accordance with Animal Care and Use Committee guidelines
of Kureha Chemical Industry.
Mixed tumour transplantation assay
The mixed tumour transplantation assay was performed by
mixing CHO/neo (3 x 10' cells) with CHO/hu-IL-8 (1 x 106
cells), or CHO/mu-MIP-la (1 x 106 cells) and injecting them
into nude mice as described above.
Histology
Tissues at the site of tumour injection were embedded in
OCT compound (Miles. Elkhart, IN, USA) and snap frozen
in liquid nitrogen. Six micron cryostat sections were fixed in
90% ethyl alcohol and stained with haematoxylin and eosin.
Statistical analysis
Values in the table are expressed as the mean ± s.e. The
significance of the differences was calculated using the
Student's t-test. Values of P<0.05 were considered to be
significant.
Results
Production ofchemokine in transfectants
Twelve independent G418-resistant colonies from each
transfection of chemokine expression plasmid were isolated
and expanded. One clone showing the highest level of mRNA
expression for chemokine was selected for further study by
the RNA blotting method, as shown in Figure 1. The CHO
cells transfected with vector alone (CHO/neo: control) did
not express any cross-hybridising endogenous chemokine
genes. Furthermore, the production of chemokine was
confirmed by assays of chemotactic activity, ELISA and/or
RIA (Table I). Individual transfectants secreted substantial
levels of chemokine activity, while control transfectant pro-
duced no chemotactic factor.
Inhibition of tumour growcth in vivo
The transfection and expression of chemokine by CHO cells
did not alter their growth properties in vitro as assayed by
doubling time or morphology (data not shown). Chemokine
gene-transfected clones as well as parental CHO cells trans-
fected with vector alone were tested for tumorigenicity by s.c.
transplantation into the flank of immunoincompetent nude
mice (T-cell deficient). Figure 2 shows representative results
from three experiments of the in vivo growth rate of
chemokine transfectants. CHO/hu-MIP-2, CHO/hu-MCP-l,
and CHO/mu-MCP-l showed almost the same growth rate
as control cells (CHO/neo) in vivo, whereas hu-IL-8-, mu-
and hu-MIP- x-expressing clone (CHO,'u-IL-8, CHO/mu-
MIP-la and CHO/hu-MIP-luz) grew significantly more slowly
than control cells (CHO/neo). Table II shows tumour
incidence and final tumour weight as assayed at 22 days after
transplantation. The production of hu-IL-8 or hu- or mu-
MIP-lac by tumour cells was associated with markedly supp-
ressed tumour growth in nude mice. The growth inhibition
was 86.7% for CHO/hu-IL-8, 30.7% for CHO/hu-MIP-l(z
and 94.4% for CHO/mu-MIP-Iz. Furthermore, tumour for-
mation was totally prevented in four of seven mice in the
case of CHO/hu-IL-8 and in four of nine mice for CHO/mu-
MIP-la. In contrast, secretion of hu-, mu-MCP-l or mu-
MIP-2 by tumour cells did not cause a reduction or preven-
tion of tumour growth.
Mixed tumour transplantation assay
Additional insight into the mechanism by which secretion of
hu-IL-8 or mu-MIP-lac by a tumour suppressed cell growth
in vivo came from assays of injections of tumour mixtures in
which 3:1 mixtures of CHO/neo and CHOlhu-IL-8, or CHO
mu-MIP-lx cells were injected into nude mice. Although
CHO/neo-tumour arose in 100% of animals, tumour
developed in seven of nine or six of nine animals injected
with a mixture of CHO/neo and CHO/hu-IL-8 or of CHO
neo and CHOjmu-MIP-la respectively, as shown in Table III.
Histology at the site oftumour cell injection
To elucidate the host cellular responses activated by
chemokine production, histological analysis of the injection
site was performed at 48 h after tumour cell (3 x 106).
challenge as shown in Figure 3. Few inflammatory cells
infiltrated the CHO/neo injection site. In contrast, the
inoculation site of CHO hu-IL-8, CHO hu-MIP-la and
CHO/mu-MIP-lrt contained a marked cellular infiltrate com-
posed predominantly of neutrophils, as well as necrotic dest-
ruction of tumour cells. In contrast, the cellular infiltrate of
sites injected with CHO/bu-MCP-l, CHOimu-MCP-l and
CHO/mu-MIP-2 was very similar to that of the control
CHO/neo or CHO injected recipients.
Numerous papers have been published on the anti-tumour
effects of transfection of tumour cells with cytokine genes
(Colombo and Forni, 1994). Transfection with virtually
almost all cytokine genes results in inhibition of tumour
Table H Tumorigenicity after chemokine gene transfera
Twnour weight (g)b
Twnour (mean ± s.d.} Twnour incidence'
CHO/hu-IL-8 0.08 _ 0.04* (86.7)c 4 7
CHO/neo 0.60 0.35 7 7
CHO/hu-MIP-lcx 0.70 0.29** (30.7)c 6 6
CHO/neo 1.01 0.25 7 7
CHO/hu-MCP-1 1.01 0.06 7 7
CHO/neo 1.08 0.11 7 7
CHO/mu-MIP-l 0.05 ± 0.01* (94 4)c 4 9
CHO/neo 1.07 0.11 9 9
CHO/mu-MIP-2 0.87 0.35 8 8
CHO/neo 0.50 0.30 8 8
CHO mu-MCP-l 0.50 0.16 8 8
CHO neo 0.72 0.28 8 8
'Mice were injected s.c. with 3 x 10' cells of tumour. iTumour
weight and incidence (number of mice with tumour/number of mice
injected) refer to day 22 after transplantation. cGrowth inhibition
(%). *P<0.001 vs CHO/neo (control) (Student's t-test). **P<0.01
vs CHO neo (Student's t-test).
Table III The effect of chemokines in mixed tumour
transplantation'
Tumour Twnour incidenceb
CHO,neo alone 9 9
CHO/neo plus CHO hu-IL-8 7 9
CHO/neo plus CHO/mu-MIP-lcx 6 9
"Mice were injected s.c. with CHO neo (3 x 106 cells) alone. or a
mixture of CHO neo (3 x 106 cells) and chemokine-producing CHO
(1 x 106 cells). 'Tumour incidence (number of mice with
tumour/number of mice injected) refer to day 22 after
transplantation.
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growth, mediated through infiltration of T lymphocytes and/
or macrophages into the tumour site.
Ours is the first report demonstrating the inhibition of
tumour growth in nude mice by secretion of IL-8 or MIP-1x,
and this was accompanied by neutrophilic infiltration. Both
CHO
purified IL-8 and MIP-I have been reported to act on
several types of immune cells (Oppenheim et al., 1991) but
did not show tumour cell killing activity in vitro. On the basis
of their in vitro properties (Wolpe and Cerami, 1989;
Oppenheim et al., 1991), IL-8 and MIP-lac are reported to
CHO/neo
CHO/hu-MIP-1 a CHO/mu-MIP-1 a
i ^S-.a- r 2 %
CHO/hu-IL-8 CHO/mu-MIP-2
CHO/hu-MCP-1 CHO/mu-MCP-1
Figwe 3 Cellular infiltrate at the injection site ofchemokine-producing CHO cells. Nude mice were injected s.c. with 3 x 106 cells.
The mice were sacrificed 48 h later and the injection sites were processed for histological examination. All sections were stained
with haematoxylin and eosin. Magnification x 200.c I.. -guFMuiaferreduces tmorin wipidy in vo
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attract neutrophils and, perhaps, to activate anti-tumour pro-
perties of neutrophils. If neutrophils are responsible for
tumour-growth suppression in nude mice, there are several
possible mechanisms whereby IL-8- or MIP-Icl-activated
neutrophils might exert their effects. These chemokines
activate neutrophils to release cytotoxic oxygen radicals and/
or proteases, which could kill tumour cells. It is also possible
for neutrophils to produce a soluble mediator of tumour cell
killing such as TNF, IL-I and IFNs in response to these
chemokines, since neutrophils have been reported to be
potent producers of cytokines (Lloyd and Oppenheim, 1992).
Interestingly, mu-MIP-2, which has also been reported to be
a chemokine for neutrophils in vitro (Anisowicz et al., 1987),
showed only a very low level of neutrophilic infiltration,
similar to that of the controls, and had no anti-tumour
activity. This was perhaps due to insufficient attraction of
neutrophils by the MIP-2-transfected cells. Although two
research groups have independently demonstrated MCP-1
(MCAF, JE) secretion by transfected tumour induced
monocyte-mediated tumoricidal activity in syngeneic (Bottazi
et al., 1992) and nude mice (Rollins and Sunday, 1991), we
did not observe the suppression of tumour growth and
monocytic infiltration at the injection site of MCP-1-
producing tumour cells. This discrepancy might derive from
differences in the level of MCP-1 production by tumour cells.
We may not have achieved optimal concentration of this
chemokine for chemotactic effects on monocytes in vivo. It is
also possible that CHO cells spontaneously produce certain
cross species-reactive cytokines which may have influenced
the chemotactic activities of chemokine produced by the
transfectants.
We have observed that mu-MIP-lcx had much more potent
tumoricidal activity than hu-MIP-lI in nude mice, perhaps
because of species differences. Histological examination dem-
onstrated that mu-MIP-lI resulted in greater accumulation
in mu-neutrophils than hu-MIP-lcm. Nevertheless, hu-MIP-lac
is quite cross species-reactive, as previously reported (Dunlop
et al., 1992). The mixed tumour transplantation assay dem-
onstrated that the effects of hu-IL-8 and mu-MIP-hi were
transmitted from producer to non-producer cells.
It was recently reported that gene transfer of IP-10, which
is a member of the C-X-C chemokines superfamily, elicited a
more potent host-mediated anti-tumour effect in syngeneic,
immunocompetent mice than in immunoincompetent nude
mice (Luster and Leder, 1993). The anti-tumour response of
IP-10 is T lymphocyte dependent, not limited to secreting
cells, and appears to be mediated by the recruitment of cell
infiltrate composed of T lymphocytes in vivo. Since IL-8 is,
also, a potent chemoattractant for T lymphocytes (Larsen et
al., 1989), an enhanced anti-tumour effect might be expected
in syngeneic, immunocompetent mice, but this remains to be
shown. On the other hand, MIP-la is unlikely to show more
potent anti-tumour effects in syngeneic than in nude mice,
because the injection site (s.c.) of Lewis lung carcinoma cells
transfected with mu-MIP to syngeneic mice contained very
few infiltrating T lymphocytes (data not shown).
Although IL-8 was originally identified as a neutrophil
chemoattractant, subsequent work has revealed its multifunc-
tionality, as is the case with most cytokines. IL-8 can induce
the migration of some tumour cells (Wang et al., 1990) and
stimulate the growth of melanoma cells (Schadendorf et al.,
1993). IL-8 has also been shown to be an angiogenic factor
released by activated macrophage (Koch et al., 1992; Strieter
et al., 1992). Since cell migration, proliferation and
angiogenesis are all essential components of the metastatic
process (Fidler et al., 1990), IL-8 expression by tumour cells
may influence their metastatic capabilities. In fact, a recent
paper has clearly demonstrated that the expression level of
IL-8 correlated with the metastatic potential of human
melanoma cells implanted into nude mice (Singh et al., 1994).
However, we have not observed metastatic behaviour in
CHO cells transfected with IL-8 in nude mice (data not
shown). These contradictory observations may be explained
by differences in the metastatic potential of different tumour
cell types. Factors in addition to IL-8 production might be
required for metastasis of CHO tumour cells.
The fact that MIP-bI, a C-C chemokine, results in the
accumulation of neutrophils, but not of monocytes, in our in
vivo study was quite unexpected, because C-C chemokines
have been thought to be predominantly chemotactic for
monocytes (Oppenheim et al., 1991).
The local injection of immunomodulating agents such as
LPS and PSK (protein-bound polysaccharide) (Nakazato et
al., 1994), which are potent inducers of chemokines, at the
tumour site (Matsushima et al., 1988; Hirose et al., 1990),
could lead to tumour cell killing based on local chemokine
secretion.
Chemokines may be useful clinically in combination with
anti-cancer agents and/or other types of cytokines such as
IL-2, IFNs, and CSFs, since they seem to have different
anti-tumour mechanisms and to be well tolerated at high
doses. This leads us to hypothesise that engineering tumour-
infiltrating lymphocytes (TILs) to express a chemokine might
provide synergistic local tumour cell killing.
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